Empowering the immune system to recognize and eliminate tumors has tremendous potential to change the way cancer is treated and eventually cured. At Fluidigm, we are focused on providing research solutions to help you interrogate the tumor microenvironment, blood-based cancers, and immune cell function with unprecedented resolution. From Helios™ mass cytometry and Maxpar® antibody panels that allow you to obtain high-dimensional immune phenotypes to single-cell genomics solutions that provide a comprehensive view of the tumor microenvironment, we can help you reach your next breakthrough.
Visit Fluidigm at Booth 2356
Exhibit Dates & Hours:
- Sunday, April 17: 1:00–5:00 pm
- Monday, April 18: 9:00 am–5:00 pm
- Tuesday, April 19: 9:00 am–5:00 pm
- Wednesday, April 20: 9:00 am–12:00 pm
Product Presentations
Complete end-to-end single-cell workflows and targeted next generation sequencing solutions from Fluidigm allow you to examine both cancer cells and immune cells from every angle.
Helios, a CyTOF® SystemIdentify immune signatures using single-cell proteomic profiling |
 |
C1™Reveal the tumor microenvironment at single-cell resolution. |
 |
Polaris™Explore cancer cell function at the single-cell level. |
 |
Juno™Simplify targeted NGS library prep, gene expression and genotyping of genes related to tumor progression. |
 |
2016 AACR Posters Featuring Fluidigm Technology & Presentations of Interest
Saturday, April 16
Time |
Title |
Presenting Author & Institution |
Abstract #
|
Location |
| 10:45–11:10 am | The many faces of circulating tumor cells | James Hicks,
University of Southern California |
— | Room 265 |
| 11:45 am–12:10 pm | Single cell transcriptomics and its application to cellular phenotyping of primary tumors | Paul Robson,
The Jackson Laboratory |
— | Room 265 |
| 1:00–1:25 pm | Leukemic stem cells lie at the origin of AML relapse | John Dick,
University of Toronto |
— | Room 265 |
|
3:15–3:35 pm |
Highly multiplexed imaging of tumor tissues by mass cytometry for precision medical applications
|
Bernd Bodenmiller, University of Zurich |
— |
New Orleans Theater B |
| 4:15–4:35 pm | Integrated (epi)genome and transcriptome sequencing from single cells: principles and applications in cancer | Ian C. Macaulay, Wellcome Trust Sanger Institute
|
— | New Orleans Theater B |
Sunday, April 17
Time |
Title |
Presenting Author & Institution |
Abstract #
|
Location |
|
7:00–8:00 am |
Making the most of single-cell RNAseq data |
Dana Pe’er,
|
— |
Room 354 |
|
1:00–5:00 pm |
Identification of the carcinoma and immune cells in the breast cancer by single-cell RNA sequencing |
Woosung Chung,
|
160/14 |
Section 6 |
|
|
Single-cell RNA sequencing presents explicit expression signatures in primary breast cancer |
Hye Hyeon Eum,
|
161/15 |
Section 6 |
Monday, April 18
Time |
Title |
Presenting Author & Institution |
Abstract #
|
Location |
|
8:00 am–12:00 pm |
A systems immunology analysis to detect prognostic biomarkers in patients with squamous cell carcinomas of the head and neck |
Cariad Chester,
|
1401/2 |
Section 22 |
|
|
Molecular subtypes of breast cancers and normal mammary epithelial cells show hierarchical heterogeneity and complexity at single-cell resolution |
Ebrahim Azizi,
|
1585/2 |
Section 30 |
|
|
Epithelial mesenchymal transition generates cancer stem cells in CD44- colorectal cancer cells |
Michitaka Nakano,
|
1707/4 |
Section 34 |
|
|
The role of CD44v9+ colorectal cancer stem cells in the resistance to cetuximab treatment |
Chia-Nung Hung,
|
1716/13 |
Section 34 |
|
1:00–5:00 pm |
Comprehensive RNA-seq transcriptome interrogation of paired hepatocellular carcinoma and cirrhosis tissues revealed significant molecular features of disease evolution and modulation of tumor immunity |
Bonnie P. Liu,
|
1837/5 |
Section 3 |
|
|
Single-cell multiplexed profiling of protein-level changes induced by EGFR inhibitor gefitinib |
Ilona Holcomb,
|
1853/21 |
Section 3 |
|
|
Simultaneous profiling of mRNA and protein in single human induced pluripotent stem cells | Benjamin Liu,
Flluidigm |
LB-147/1 | Section 10 |
|
|
The immune modulatory roles of IAP inhibitor, LCL161, and its connection to immune-checkpoint molecules |
Maria Pinzon-Ortiz,
|
2343/27 |
Section 26 |
|
|
The polyclonal nature of multinodular goitre revealed by DICER1 sequencing |
Leanne de Kock,
|
2390/20 |
Section 28 |
|
3:35–3:50 pm |
In depth immune profiling of the response of melanoma to MAPK inhibition |
Sarah J. Welsh,
|
2650 |
Theater B |
|
3:50–4:05 pm |
Relapse in BCP-ALL predicted by activated signaling in pro-B cell subsets |
Zinaida Good,
|
2693 |
Room 354 |
Tuesday, April 19
Time |
Title |
Presenting Author & Institution |
Abstract #
|
Location |
|
8:00 am–12:00 pm |
Expression of CD14 and SIRP-α defines distinct populations of intratumoral monocytes/macrophages in B-cell non-Hodgkin lymphomas |
Ya-Ping Chen,
|
3287/7 |
Section 29 |
|
|
Riboflavin targets autofluorescent-positive breast cancer stem cells upon light exposure |
Shamileh Fouladdel, University of Michigan |
3310/8 |
Section 31 |
|
|
Single-cell analysis reveals molecular mechanisms of NRAS-mediated leukemia stem cell self-renewal in a murine model of AML |
Rebecca S. LaRue, University of Minnesota |
3339/7 |
Section 32 |
|
1:00–5:00 pm |
Single cell dual adherent-suspension co-culture microenvironment for studying tumor-stromal interactions in breast cancer stem cells |
Yu-Chih Chen,
|
4076/3 |
Section 29 |
|
|
Circulating vitamin D2 and D3 levels and single nucleotide polymorphism associations with lung cancer status: a case-control study |
Majda Haznadar,
|
4320/11 |
Section 37 |
|
|
Gene expression and genomic drift comparative analysis between patient-derived conditionally reprogrammed cells and original tumors |
Jessica Li,
|
4257/7 |
Section 35 |
Wednesday, April 20
Time |
Title |
Presenting Author & Institution |
Abstract #
|
Location |
|
7:30–11:00 am |
Isolation and mRNA-seq analysis of single CTCs from blood samples using an integrated fluidic circuit (IFC) for functional single cell studies |
Lukasz Szpankowski
|
5035A/30 |
Section 27 |
|
8:00 am–
|
Intratumoral HPV16-specific T-cells determine clinical outcome of HPV16+ oropharyngeal carcinomas |
Marij J. Welters,
|
5035A/30 |
Section 27 |
Social Media
Can’t make it to all of the sessions? Follow @fluidigm with #AACR16 and like us on Facebook for scientific and event updates.